Fremanezumab

Summary

Fremanezumab (CHEMBL4297756) is an approved antibody (ATC N02CD03); indicated across 4 conditions including migraine disorder and fibromyalgia.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Antibody
• ATC class: N02CD03
• Indications: 4 conditions
• Clinical trials: 30

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297756
Name	Fremanezumab
Type	Antibody
Max phase	4
ATC	N02CD03

Also known as: Ajovy, Fremanezumab, Fremanezumab vfrm, Fremanezumab-vfrm, LBR-101, LBR101, PF-04472429, PF04472429, RN-307, RN307, Tev-48125, TEV-48125

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
migraine disorder	4	MONDO:0005277	MONDO:0005277

2 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
fibromyalgia	2	MONDO:0005546	EFO:0005687
interstitial cystitis	2	MONDO:0018301	EFO:0008507

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 30.

Phase distribution

Phase	Trials
PHASE3	12
Not specified	8
PHASE4	4
PHASE2	4
PHASE2/PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06173661	PHASE4	ACTIVE_NOT_RECRUITING	Fremanezumab Treatment of Migraine in Women With Menstrual Migraine Ages 18-45
NCT04041284	PHASE4	COMPLETED	A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder
NCT04461795	PHASE4	COMPLETED	Efficacy of AJOVY (Fremanezumab-vfrm) on Interictal Migraine Related Burden
NCT05284019	PHASE4	TERMINATED	Real World Effectiveness of Eptinezumab in Participants With Migraine
NCT02621931	PHASE3	COMPLETED	Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine
NCT02629861	PHASE3	COMPLETED	Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for the Preventive Treatment of Episodic Migraine
NCT02638103	PHASE3	COMPLETED	Efficacy and Safety of Subcutaneous Administration of Fremanezumab (TEV-48125) for the Preventive Treatment of Migraine
NCT02945046	PHASE3	TERMINATED	A Study to Evaluate the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Episodic Cluster Headache (ECH)
NCT02964338	PHASE3	TERMINATED	A Study Comparing the Efficacy and Safety of Fremanezumab (TEV-48125) for the Prevention of Chronic Cluster Headache (CCH)
NCT03107052	PHASE3	TERMINATED	A Study to Explore the Long-Term Safety and Efficacy of Fremanezumab (TEV-48125) for the Prevention of Cluster Headache
NCT03303079	PHASE2/PHASE3	COMPLETED	Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Chronic Migraine
NCT03303092	PHASE2/PHASE3	COMPLETED	Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Episodic Migraine
NCT03303105	PHASE3	COMPLETED	Long-term Safety and Tolerability of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
NCT03308968	PHASE3	COMPLETED	An Efficacy and Safety Study of Fremanezumab in Adults With Migraine
NCT04458857	PHASE3	COMPLETED	A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of Age
NCT04464707	PHASE3	COMPLETED	A Study to Test if Fremanezumab is Effective in Preventing Chronic Migraine in Participants 6 to 17 Years of Age
NCT04530110	PHASE3	COMPLETED	A Study to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents
NCT05458011	PHASE3	COMPLETED	A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period on Efficacy and Safety of Fremanezumab in Chinese Adults With Migraine
NCT03347188	PHASE2	COMPLETED	A Study to Test if Fremanezumab Reduces Headache in Participants With Posttraumatic Headache (PTH)
NCT03965091	PHASE2	TERMINATED	A Study to Test the Effectiveness and Safety of Fremanezumab on Participants With Fibromyalgia
NCT04334408	PHASE2	WITHDRAWN	Safety and Efficacy of Fremanezumab for Migraine in Adult CADASIL
NCT04447729	PHASE2	WITHDRAWN	A Study to Test if Fremanezumab Reduces Pain in Patients With Interstitial Cystitis-Bladder Pain Syndrome
NCT03539393	Not specified	AVAILABLE	Fremanezumab Compassionate Use Program for Pediatric Patients
NCT04628429	Not specified	RECRUITING	CGRP Inhibition, Autonomic Function, and Migraine
NCT05342493	Not specified	RECRUITING	Specified Drug Use Survey on AJOVY Subcutaneous Injection for Long-term Use
NCT06212661	Not specified	ENROLLING_BY_INVITATION	Migraine Medication Effects on Urinary Symptoms
NCT06659120	Not specified	RECRUITING	Fremanezumab for the Prevention of Menstrually-related Migraine Attacks
NCT07029126	Not specified	RECRUITING	Improving the Perception of Stress and Mutuality in Caregivers (MI-DEAR Study) of Migraine Patients With Depressive Symptoms Treated With Fremanezumab: A Study to Evaluate Whether Fremanezumab Reduces the Impact on Caregivers and Increases Couple Reciprocity
NCT04547179	Not specified	UNKNOWN	Medicinal vs. Orthotic Comparison for Migraine Prevention: A Double-Blind Study
NCT05281770	Not specified	UNKNOWN	Monoclonal CGRP Antibodies for Migraine Prevention - a Nationwide Real Life Study

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).